InsidersTradesSigma
Follow the 新华制药 share price and the full management transaction log of the company, a publicly traded company based in China. Shares are listed on the CN market, under the supervision of SSE / SZSE (CSRC). Operating in the Health Care sector, 新华制药 has recorded 4 public disclosures. Market capitalisation: €9.4bn. The latest transaction was reported on 29 July 2022 (Sale). Among the most active insiders: 王小龙. All data is openly available.
4
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€255,367
4 ops.
Sell Volume
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 16,136 of 29,064 companies
48.9
score / 100
Value56
Quality42
FCF yld4.4%
Earn yld3.1%
EV/EBITDA11.0x
ROE5.0%
Gross mgn19%
Net mgn3.3%
Debt/EBITDA1.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 29 July 2022
关于 新华制药
新华制药是一家总部位于中国的制药公司，专注于药品的制造。它致力于仿制药和创新药物的开发和生产。